South San Francisco, United States
Nkarta, Inc., founded in 2015, is at the forefront of innovative biotechnology solutions aimed at tackling autoimmune diseases. Their slogan, "A New Way Forward for Autoimmune Disease", reflects their pioneering approach in the Biotechnology and Health Care sectors.
The company specializes in developing allogeneic natural killer (NK) cell therapies. Utilizing a unique combination of cell expansion, cryopreservation platforms, and proprietary cell engineering technologies, Nkarta is advancing a promising pipeline of cell therapy candidates. These candidates benefit from efficient manufacturing processes and are specially designed to enhance tumor targeting and improve persistence within the body.
Headquartered in the United States, Nkarta secured a substantial $240.00M post-IPO equity investment on 25 March 2024, backed by a strong coalition of investors including RA Capital Management, OrbiMed, Adage Capital Management, Commodore Capital, EcoR1 Capital, Janus Henderson, Ridgeback Capital, Samsara BioCapital, SR One, and Cormorant Asset Management. This investment underscores the investor confidence in Nkarta's groundbreaking work and growth potential in the field of biotechnological therapeutics.
